Kaiser Peter 4

4 · OCULAR THERAPEUTIX, INC · Filed May 28, 2026

AI-generated summary of this filing

Updated May 28, 2026

Ocular Therapeutix CDO Peter Kaiser Sells 2,967 Shares

What Happened

Peter Kaiser, Chief Development Officer of Ocular Therapeutix (OCUL), disposed of 2,967 shares on May 26, 2026, for a reported weighted-average price of $8.20 per share, totaling approximately $24,329. This was a sale (S) executed under an automatic instruction and was not a discretionary trade.

Key Details

Transaction date: 2026-05-26 (reported on Form 4 filed 2026-05-28) — filing appears timely.
Price: weighted average $8.20; individual sale prices ranged from $8.1549 to $8.2550.
Reason/footnote: Sold pursuant to a durable automatic sale instruction (adopted April 9, 2024) as a sell-to-cover to satisfy tax withholding for restricted stock units that vested May 22, 2026 (Footnote F1).
Multiple trades: shares sold in multiple transactions across the stated price range; filer offers to provide per-price details on request (Footnote F2).
Shares owned after transaction: not specified in the provided filing.

Context

This was a routine sell-to-cover tied to RSU vesting and an automatic instruction — common for meeting tax obligations and not necessarily an indicator of the insider’s view on the company’s stock. The filing discloses the weighted-average price and the non-discretionary nature of the sales.

Form 4

Period: 2026-05-26

Chief Development Officer

Transactions

Footnotes (2)

[F1]Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1549 to $8.2550, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Signature

/s/ Todd Anderman, Attorney-in-Fact for Peter Kaiser|2026-05-28

1 file